Jul 31, 2025 8:00am EDT Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Jul 16, 2025 8:00am EDT Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
March 3, 2025 Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
December 20, 2023 Navigating the Future of Pain Management: Ensysce Biosciences’ Innovative Approach